MedTrace Logo

Phase 1 Safety Study of Single and Multi-Dose Topically Applied OLT1177 Gel in Healthy Subjects

NCT01636141 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2012-09-06

No results posted yet for this study

Summary

The purpose of this study is to determine if OLT1177 Gel is safe and can be tolerated when given as a single dose and multidose to a defined area of one knee of healthy subjects.

Conditions

  • Healthy Volunteers

Interventions

DRUG

OLT1177 Gel

OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee

DRUG

Placebo gel

Sponsors & Collaborators

  • Olatec Therapeutics LLC

    lead INDUSTRY

Principal Investigators

  • Terry M Jones, MD · J&S Studies

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2012-08-31
Completion
2012-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01636141 on ClinicalTrials.gov